Evidence map›Paper›PMID 37118348›Full record

ArticlePharmaceutical research2023

Strategies To Stabilize Dalbavancin in Aqueous Solutions; Section 3: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Phosphate Buffer with and without Divalent Metal Ions.

Sardar M Jakaria, David E Budil, James Murtagh

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Sardar M JakariaHikma Pharmaceuticals, Bedford, OH-44146, USA. sjakaria@hikma.com.ORCID http://orcid.org/0000-0002-8887-230X
David E BudilDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA-02115, USA.ORCID http://orcid.org/0000-0003-2384-7928
James MurtaghHikma Pharmaceuticals, Bedford, OH-44146, USA.
Northeastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNew formulations of the glycopeptide drug dalbavancin containing 2-hydroxpropyl-β-cyclodextrin (2HPβCD) with or without divalent metal ions in phosphate buffer (pH 7.0) were tested to evaluate whether these excipients influence the aqueous solution stability of dalbavancin.

methodRecovery of dalbavancin from phosphate buffered solutions at pH 7.0 with different concentrations of 2HPβCD and a divalent metal ion (Ca

resultsDalbavancin solutions with either 5.5 mM or 55 mM 2HPβCD were significantly more stable with Mg

conclusionThe results suggest that 2HPβCD forms an inclusion complex with dalbavancin that slows the formation of the major degradant, mannosyl aglycone (MAG). The effect of 2HPβCD is increased in the presence of Mg

Indexed as

ExcipientsTeicoplanin2-Hydroxypropyl-beta-cyclodextrinDrug StabilityHydrogen-Ion ConcentrationSolutionsWater2-Hydroxypropyl-beta-cyclodextrindalbavancinExcipientsSolutionsTeicoplaninWater2-hydroxypropyl-β-cyclodextrinDalbavancin formulationDalbavancin injection solutionDivalent metal ionInclusion complexStability in phosphate buffer

Identifiers

PMID37118348
OpenAlexW4367303473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.